Tisdag 15 September | 10:47:33 Europe / Stockholm
Svenska | English
Kursutveckling under dagen för detta pressmeddelande (SEK).
Likviditet under dagen för detta pressmeddelande
Est. tid*
2027-01-21 N/A X-dag ordinarie utdelning NEWBRY 0.00 SEK
2027-01-20 N/A Årsstämma
2027-01-20 08:00 Kvartalsrapport 2027-Q1
2026-10-28 08:00 Bokslutskommuniké 2026
2026-07-08 - Kvartalsrapport 2026-Q3
2026-04-15 - Extra Bolagsstämma 2026
2026-04-15 - Kvartalsrapport 2026-Q2
2026-01-21 - Kvartalsrapport 2026-Q1
2026-01-14 - Årsstämma
2025-10-29 - Bokslutskommuniké 2025
2025-07-09 - Kvartalsrapport 2025-Q3
2025-04-09 - Kvartalsrapport 2025-Q2
2025-01-24 - Kvartalsrapport 2025-Q1
2025-01-16 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15 - Årsstämma
2024-10-23 - Bokslutskommuniké 2024
2024-07-31 - Extra Bolagsstämma 2024
2024-07-10 - Kvartalsrapport 2024-Q3
2024-04-10 - Kvartalsrapport 2024-Q2
2024-01-11 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 - Årsstämma
2024-01-10 - Kvartalsrapport 2024-Q1
2023-10-11 - Bokslutskommuniké 2023
2023-07-14 - Kvartalsrapport 2023-Q3
2023-04-12 - Kvartalsrapport 2023-Q2
2023-01-12 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 - Årsstämma
2023-01-11 - Kvartalsrapport 2023-Q1
2022-10-13 - Bokslutskommuniké 2022
2022-07-06 - Kvartalsrapport 2022-Q3
2022-04-13 - Kvartalsrapport 2022-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Export order received

2022-02-07 10:00:00

Newbury Pharmaceuticals AB’s subsidiary in Switzerland received an international export order of private label pharmaceuticals with a total value of approx. 370 KUSD. Shipment of the order is planned in May.

The subsidiary in Switzerland conducts international sales of pharmaceuticals outside of Scandinavia. Although Newbury’s focus is on the Scandinavian markets, export opportunities arise which contribute to improved sales and profitability.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Export order received

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden